iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/35677450/
Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 23:13:921517.
doi: 10.3389/fphar.2022.921517. eCollection 2022.

Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection

Weizheng Liang  1   2 , Xiushen Li  3   4   5 , Yue Yao  6 , Qingxue Meng  1 , Xueliang Wu  2 , Hao Wang  3   4   5 , Jun Xue  1   2
Affiliations

Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection

Weizheng Liang et al. Front Pharmacol. .

Abstract

Patients with colonic adenocarcinoma (COAD) are at relatively high risk of SARS-CoV-2 infection. However, there is a lack of medical strategies to treat COVID-19/COAD comorbidity. Puerarin, a natural product, is a known antiviral, antitumor, and immunomodulatory effect. Therefore, we hypothesised that puerarin could be used to treat COVID-19/COAD patients. Based on network pharmacology and bioinformatics analysis, the potential targets and pharmacological mechanisms of puerarin in COVID-19/COAD were identified. By intersecting therapeutic target genes for puerarin, COVID-19-related genes and COAD-related genes, 42 target genes of puerarin that could potentially treat COVID-19/COAD comorbidity were obtained. By using the 42 potential target genes to construct the protein-protein interaction (PPI) network, we obtained five core target genes, namely RELA, BCL2, JUN, FOS, and MAPK1. The results of bioinformatics analysis revealed that puerarin could be able to treat COVID-19/COAD comorbidity through apoptosis, antiviral, antioxidant, NF-κB signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway etc. This study found that puerarin has the potential to treat COVID-19/COAD patients and that the therapeutic target genes obtained in the study may provide clues for the treatment of COVID19/COAD comorbidity.

Keywords: COAD; COVID-19; bioinformatics; comorbidity; network pharmacology; puerarin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart. This study followed the analytical flow of the flowchart to explore the target genes and molecular mechanisms of puerarin in the treatment of COAD/COVID-19.
FIGURE 2
FIGURE 2
DEGs from COAD patients or COVID-19 patients (p < 0.05 and absolute value of log fold change >1). The red and blue dots represented genes with increased or decreased expression in COVID-19 patients or COAD patients, respectively, while the black dots represented genes with no significant difference in expression between COVID-19 or COAD patients. (A) Volcano plot of DEGs in the GSE152075 dataset. (B) Volcano plot of DEGs in the GSE157103 dataset. (C) Volcano plot of DEGs in the GSE171110 dataset. (D) Volcano plot of DEGs in the TCGA-COAD dataset and the GTEx-CO dataset.
FIGURE 3
FIGURE 3
Potential target genes of puerarin in the treatment of COVID-19/COAD comorbidity. (A) Genes associated with COVID-19 from 3 GEO datasets and six databases. (B) Genes associated with COAD from the TCGA-COAD dataset, GTEx-CO dataset, and seven databases. (C) Therapeutic target genes of Puerarin from seven databases. (D) Venn diagram of therapeutic target genes for puerarin, COVID-19-related genes and COAD-related genes.
FIGURE 4
FIGURE 4
PPI network of potential therapeutic target genes of puerarin in the treatment of COVID-19/COAD. (A) The PPI network was derived from the GeneMANIA database. The different relationships between nodes were indicated by the different colored connecting lines. Nodes were enriched in different functions indicated by the colors of the nodes. (B) PPI networks constructed from nodal degree values. The degree of the node was proportional to the depth of the node color.
FIGURE 5
FIGURE 5
GO and KEGG enrichment analysis of potential therapeutic target genes of puerarin for COVID-19/COAD (only the 20 pathways with the smallest p-values were shown). (A), (C) and (E) The results of BP, CC, and MF term enrichment analysis, respectively. (B), (D) and (F) The results of correlation analysis of BP, CC, MF term enrichment analysis, respectively. (G) The results of KEGG enrichment analysis. (H)The results of correlation analysis of KEGG enrichment analysis.
FIGURE 6
FIGURE 6
Top five enrichment analysis results and corresponding genes. (A), (B) and (C)The top five results of BP, CC, MF enrichment analysis and corresponding genes. (D) The top five results of KEGG enrichment analysis and the corresponding genes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ashida R., Tominaga K., Sasaki E., Watanabe T., Fujiwara Y., Oshitani N., et al. (2005). AP-1 and Colorectal Cancer. Inflammopharmacology 13 (1-3), 113–125. 10.1163/156856005774423935 - DOI - PubMed
    1. Badawi A. (2020). Hypercytokinemia and Pathogen-Host Interaction in COVID-19. J. Inflamm. Res. 13, 255–261. 10.2147/jir.S259096 - DOI - PMC - PubMed
    1. Barrett C. W., Short S. P., Williams C. S. (2017). Selenoproteins and Oxidative Stress-Induced Inflammatory Tumorigenesis in the Gut. Cell Mol. Life Sci. 74 (4), 607–616. 10.1007/s00018-016-2339-2 - DOI - PMC - PubMed
    1. Braicu C., Buse M., Busuioc C., Drula R., Gulei D., Raduly L., et al. (2019). A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers (Basel) 11 (10), 1618. 10.3390/cancers11101618 - DOI - PMC - PubMed
    1. Brocato J., Chervona Y., Costa M. (2014). Molecular Responses to Hypoxia-Inducible Factor 1α and beyond. Mol. Pharmacol. 85 (5), 651–657. 10.1124/mol.113.089623 - DOI - PMC - PubMed